NASDAQ:AMRN Amarin (AMRN) Stock Price, News & Analysis $0.41 +0.00 (+0.93%) Closing price 03/14/2025 04:00 PM EasternExtended Trading$0.42 +0.01 (+1.74%) As of 03/14/2025 07:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends About Amarin Stock (NASDAQ:AMRN) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Amarin alerts:Sign Up Key Stats Today's Range$0.40▼$0.4350-Day Range$0.40▼$0.6452-Week Range$0.35▼$1.11Volume1.46 million shsAverage Volume1.46 million shsMarket Capitalization$169.94 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingBuy Company OverviewAmarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. It sells its products principally to wholesalers and specialty pharmacy providers. The company has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.Read More… Remove Ads Amarin Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks4th Percentile Overall ScoreAMRN MarketRank™: Amarin scored higher than 4% of companies evaluated by MarketBeat, and ranked 923rd out of 932 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Amarin.Read more about Amarin's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Amarin are expected to decrease in the coming year, from ($0.15) to ($0.27) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Amarin is -4.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Amarin is -4.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAmarin has a P/B Ratio of 0.31. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Amarin's valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted4.17% of the float of Amarin has been sold short.Short Interest Ratio / Days to CoverAmarin has a short interest ratio ("days to cover") of 12, which indicates bearish sentiment.Change versus previous monthShort interest in Amarin has recently decreased by 1.52%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAmarin does not currently pay a dividend.Dividend GrowthAmarin does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted4.17% of the float of Amarin has been sold short.Short Interest Ratio / Days to CoverAmarin has a short interest ratio ("days to cover") of 12, which indicates bearish sentiment.Change versus previous monthShort interest in Amarin has recently decreased by 1.52%, indicating that investor sentiment is improving. News and Social Media1.6 / 5News Sentiment-0.12 News SentimentAmarin has a news sentiment score of -0.12. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.73 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 19 news articles for Amarin this week, compared to 2 articles on an average week.Search InterestOnly 2 people have searched for AMRN on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.MarketBeat Follows3 people have added Amarin to their MarketBeat watchlist in the last 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Amarin insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.96% of the stock of Amarin is held by insiders.Percentage Held by InstitutionsOnly 22.25% of the stock of Amarin is held by institutions.Read more about Amarin's insider trading history. Receive AMRN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Amarin and its competitors with MarketBeat's FREE daily newsletter. Email Address AMRN Stock News HeadlinesAmarin (NASDAQ:AMRN) Downgraded by StockNews.com to "Sell"March 15 at 2:13 AM | americanbankingnews.comAmarin Corporation plc (NASDAQ:AMRN) Q4 2024 Earnings Call TranscriptMarch 14 at 3:11 AM | msn.comDOGE Social Security bombshell?Elon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social Security, finding what he says is widespread fraud across the agency.March 15, 2025 | Altimetry (Ad)AMRN's Q4 Earnings Lag Estimates, Stock Down on Ratio Change PlanMarch 13 at 10:11 PM | msn.comAmarin Corporation’s Earnings Call: A Mixed OutlookMarch 12 at 8:12 PM | tipranks.comAmarin Plc (AMRN) Q4 2024 Earnings Call TranscriptMarch 12 at 5:40 PM | finance.yahoo.comAmarin Corporation plc: Amarin Announces Plan to Initiate a Ratio Change Under Its American Depository Receipt (ADR) ProgramMarch 12 at 12:39 PM | finanznachrichten.deAmarin reports Q4 adjusted EPS (2c) vs. 0c last yearMarch 12 at 12:39 PM | markets.businessinsider.comSee More Headlines AMRN Stock Analysis - Frequently Asked Questions How have AMRN shares performed this year? Amarin's stock was trading at $0.4850 on January 1st, 2025. Since then, AMRN shares have decreased by 14.7% and is now trading at $0.4138. View the best growth stocks for 2025 here. How were Amarin's earnings last quarter? Amarin Co. plc (NASDAQ:AMRN) issued its earnings results on Wednesday, March, 12th. The biopharmaceutical company reported ($0.12) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.06) by $0.06. The biopharmaceutical company had revenue of $62.31 million for the quarter, compared to the consensus estimate of $32.37 million. Amarin had a negative trailing twelve-month return on equity of 7.22% and a negative net margin of 16.33%. When did Amarin's stock split? Amarin shares reverse split on Friday, April 11th 2025. The 1-20 reverse split was announced on Wednesday, March 12th 2025. The number of shares owned by shareholders will be adjusted after the market closes on Thursday, April 10th 2025. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. Does Amarin have any subsidiaries? Amarin subsidiaries include these companies: Ester Neurosciences, Amarin France SAS, Amarin Germany GmbH, Amarin Italy S.r.l, Amarin Pharmaceuticals Ireland Limited, Amarin Pharma Inc., Amarin Switzerland GmbH, Amarin UK Limited, and Ester Neurosciences Limited. Who are Amarin's major shareholders? Top institutional investors of Amarin include Waterfront Wealth Inc. (0.60%), Two Sigma Investments LP (0.53%), Two Sigma Advisers LP (0.42%) and Longitude Cayman Ltd. (0.39%). Insiders that own company stock include Aaron Berg, Steven B Ketchum, Patrick Holt and Olsen Per Wold. View institutional ownership trends. How do I buy shares of Amarin? Shares of AMRN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Amarin own? Based on aggregate information from My MarketBeat watchlists, some other companies that Amarin investors own include BMO Capital Markets (), Stifel Nicolaus (), Wunderlich (), Standpoint Research (), Duncan Williams (), Soleil Securities () and Sterne Agee CRT (). Company Calendar Last Earnings3/12/2025Today3/14/2025Next Earnings (Estimated)5/07/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:AMRN CIK897448 Webwww.amarincorp.com Phone(531) 669-9020FaxN/AEmployees360Year Founded1991Profitability EPS (Most Recent Fiscal Year)($0.09) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-59,110,000.00 Net Margins-16.33% Pretax Margin-12.34% Return on Equity-7.22% Return on Assets-4.96% Debt Debt-to-Equity RatioN/A Current Ratio3.23 Quick Ratio2.11 Sales & Book Value Annual Sales$241.02 million Price / Sales0.71 Cash FlowN/A Price / Cash FlowN/A Book Value$1.35 per share Price / Book0.31Miscellaneous Outstanding Shares410,672,000Free Float402,623,000Market Cap$169.94 million OptionableOptionable Beta1.82 Social Links 5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report This page (NASDAQ:AMRN) was last updated on 3/15/2025 by MarketBeat.com Staff From Our PartnersElon Musk Wants to Audit Fort Knox—What It Means for Your RetirementYou can take advantage of the coming tariff-fueled gold melt-up right inside your IRA or 401(k) – 100% TAX-FRE...Colonial Metals | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredAlert: DOGE goes liveElon will most likely be at the helm of it all. And just days from now, could bring about the biggest econo...Altimetry | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredTrump doesn’t give a damnPorter Stansberry: “I met with Trump’s biggest backers… they’re scooping up these 10 stocks” I recently met...Porter & Company | SponsoredThe real reason gold is soaring (and likely to continue)Trump’s Policies Are Fueling a Gold Boom—Here’s Your Chance to Profit Donald Trump’s bold policies are driv...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Amarin Co. plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Amarin With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
